ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling.

IF 2 4区医学 Q3 ONCOLOGY Oncology Research Pub Date : 2024-06-20 eCollection Date: 2024-01-01 DOI:10.32604/or.2024.045433

Xia DA, Han Ge, Junfeng Shi, Chunhua Zhu, Guozhu Wang, Yuan Fang, Jin Xu

{"title":"ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling.","authors":"Xia DA, Han Ge, Junfeng Shi, Chunhua Zhu, Guozhu Wang, Yuan Fang, Jin Xu","doi":"10.32604/or.2024.045433","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to investigate the role of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in triple-negative breast cancer (TNBC).Methods: ROR2 expression in primary TNBC and metastatic TNBC tissues was analyzed by immunohistochemical staining and PCR. ROR2 expression in TNBC cell lines was detected by PCR and Western blot analysis. The migration, invasion and chemosensitivity of TNBC cells with overexpression or knockdown of ROR2 were examined.Results: ROR2 expression was high in metastatic TNBC tissues. ROR2 knockdown suppressed the migration, invasion and chemoresistance of TNBC cells. ROR2 overexpression in MDA-MB-435 cells promoted the migration, invasion, and chemoresistance. Moreover, ROR2 knockdown in HC1599 and MDA-MB-435 adriamycin-resistant cells enhanced chemosensitivity to adriamycin. ROR2 could activate PI3K/AKT/mTOR signaling in TNBC cells.Conclusion: ROR2 is upregulated and promotes metastatic phenotypes of TNBC by activating PI3K/AKT/mTOR signaling.","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 7","pages":"1209-1219"},"PeriodicalIF":2.0000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11209745/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2024.045433","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to investigate the role of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in triple-negative breast cancer (TNBC).

Methods: ROR2 expression in primary TNBC and metastatic TNBC tissues was analyzed by immunohistochemical staining and PCR. ROR2 expression in TNBC cell lines was detected by PCR and Western blot analysis. The migration, invasion and chemosensitivity of TNBC cells with overexpression or knockdown of ROR2 were examined.

Results: ROR2 expression was high in metastatic TNBC tissues. ROR2 knockdown suppressed the migration, invasion and chemoresistance of TNBC cells. ROR2 overexpression in MDA-MB-435 cells promoted the migration, invasion, and chemoresistance. Moreover, ROR2 knockdown in HC1599 and MDA-MB-435 adriamycin-resistant cells enhanced chemosensitivity to adriamycin. ROR2 could activate PI3K/AKT/mTOR signaling in TNBC cells.

Conclusion: ROR2 is upregulated and promotes metastatic phenotypes of TNBC by activating PI3K/AKT/mTOR signaling.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

ROR2 通过激活 PI3K/AKT/mTOR 信号，促进三阴性乳腺癌细胞的侵袭和化疗抵抗。

研究目的本研究旨在探讨受体酪氨酸激酶样孤儿受体2（ROR2）在三阴性乳腺癌（TNBC）中的作用：方法：通过免疫组化染色和 PCR 分析原发性 TNBC 和转移性 TNBC 组织中 ROR2 的表达。通过 PCR 和 Western 印迹分析检测了 ROR2 在 TNBC 细胞系中的表达。检测了过表达或敲除 ROR2 的 TNBC 细胞的迁移、侵袭和化疗敏感性：结果：ROR2在转移性TNBC组织中高表达。结果：ROR2在转移性TNBC组织中高表达，ROR2敲除抑制了TNBC细胞的迁移、侵袭和化疗耐受性。ROR2 在 MDA-MB-435 细胞中的过表达促进了细胞的迁移、侵袭和耐药性。此外，在HC1599和MDA-MB-435阿霉素耐药细胞中敲除ROR2可增强细胞对阿霉素的化疗敏感性。ROR2可激活TNBC细胞的PI3K/AKT/mTOR信号转导：结论：ROR2上调并通过激活PI3K/AKT/mTOR信号促进TNBC的转移表型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology Research 医学-肿瘤学

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.